4'-bromo-Resveratrol |
| رقم الكتالوجGC17922 |
4'-Bromo-resveratrol هو مثبط قوي ومزدوج Sirtuin-1 و Sirtuin-34'-Bromo-resveratrol يمنع نمو خلايا سرطان الجلد من خلال إعادة برمجة التمثيل الغذائي للميتوكوندريايضفي 4'-Bromo-resveratrol تأثيرات مضادة للتكاثر في خلايا الورم الميلانيني من خلال إعادة البرمجة الأيضية والتأثير على دورة الخلية وإشارات موت الخلايا المبرمج
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1224713-90-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
4'-bromo-Resveratrol is a Sirt1 and Sirt3 inhibitor.
Sirtuins are protein deacetylases regulating aging processes and many physiological functions. Resveratrol activates human Sirt1 and inhibits Sirt3, and can mimic calorie restriction effects including lifespan extension in lower organisms.
In vitro: Sirtuin modulation was studied by using 4’-bromo-resveratrol in a previous study. 4’-bromo-Resveratrol inhibited Sirt3 with much higher potency than resveratrol, and it also inhibited rather than activated Sirt1. Crystal structures of human Sirt3/peptide complexes of 4’ -bromo-resveratrol identified two binding sites. An internal site caused the potent inhibitory effect. 4’-bromo-Resveratrol interfered with NAD+ and substrate peptide binding, and it extended its bromo-phenyl group in a unrecognized site pocket. The second binding site for 4’-bromo-resveratrol was found to be located on the surface of Sirt3 and connected via two helices to peptide-binding active site loops. In Sirt1, this site appeared to comprise a residue that was essential for its activation by small molecules and 4’-bromo-resveratrol therefore constituted a candidate for the long-sought allosteric Sirt1 activator binding site [1].
In vivo: So far, there is no animal in vivo data for 4'-bromo-resveratrol.
Clinical trial: Up to now, 4'-bromo-resveratrol is still in the preclinical development stage.
Reference:
[1] Nguyen GT, Gertz M, Steegborn C. Crystal structures of Sirt3 complexes with 4'-bromo-resveratrol reveal binding sites and inhibition mechanism. Chem Biol. 2013 Nov 21;20(11):1375-85.
| Cas No. | 1224713-90-9 | SDF | |
| Chemical Name | 5-[(1E)-2-(4-bromophenyl)ethenyl]-1,3-benzenediol | ||
| Canonical SMILES | OC1=CC(O)=CC(/C=C/C2=CC=C(Br)C=C2)=C1 | ||
| Formula | C14H11BrO2 | M.Wt | 291.1 |
| الذوبان | ≤50mg/ml in ethanol;50mg/ml in DMSO;100mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4352 mL | 17.1762 mL | 34.3525 mL |
| 5 mM | 0.687 mL | 3.4352 mL | 6.8705 mL |
| 10 mM | 0.3435 mL | 1.7176 mL | 3.4352 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *